EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual Specificity Phosphatase 4 Enhances Immunotherapy Response by Inhibiting TGF-β1 Secretion in Hepatocellular Carcinoma

Lian-Pan Su, Wei-Yi Wang, Xiao-Dan Ma iD, Shi-Hui Hao

Cancers · 19.04.2026 · 18 (8) · 1289

DOI: 10.3390/cancers18081289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 19.04.2026. Verfasst von Lian-Pan Su und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tumor immune microenvironment (TIME) heterogeneity limits immunotherapy efficacy in hepatocellular carcinoma (HCC), underscoring the need for predictive biomarkers and therapeutic targets. We previously identified dual specificity phosphatase 4 (DUSP4) as a mediator of sorafenib resistance, but its immunomodulatory role remains unknown.

Methods

Glypican-3 (GPC3)-specific chimeric antigen receptor (CAR) T-cell cytotoxicity assays were performed to assess the impact of DUSP4 on HCC immune susceptibility. A subcutaneous tumor model using Dusp4-overexpressing cells in female C57BL/6J mice was established to evaluate DUSP4-mediated microenvironment remodeling and anti-PD-L1 therapy efficacy. Bulk RNA sequencing of DUSP4-overexpressing HCC cells identified downstream pathways. Public datasets were interrogated to correlate DUSP4 expression with immune checkpoint blockade (ICB) response and immune infiltration in HCC.

Results

DUSP4 overexpression significantly enhanced HCC cell susceptibility to CAR-T cell killing in vitro and potentiated anti-PD-L1 efficacy in vivo, accompanied by TIME remodeling. Mechanistically, RNA sequencing revealed DUSP4-mediated downregulation of the TGF-β signaling pathway, functionally confirmed using a neutralizing antibody that abrogated the enhanced CAR-T killing. Public datasets confirmed associations between DUSP4 expression and enhanced immune cytolytic activity with favorable prognostic outcomes in HCC.

Conclusions

DUSP4 serves as a critical molecular nexus linking targeted therapy resistance to enhanced immunotherapy sensitivity. By attenuating the TGF-β signaling pathway, DUSP4 reprograms TIME toward an immunologically active state, thereby augmenting the efficacy of immunotherapy. These findings establish DUSP4 as a promising dynamic biomarker for guiding sequential therapy in HCC and highlight its potential as a novel therapeutic target to improve outcomes in solid tumor immunotherapy.

Schlagwörter

Stichwörter der Autor:innen

dual specificity phosphatase 4hepatocellular carcinomaimmune checkpoint blockadeimmune evasiontransforming growth factor-β

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

ORCID-Profile: Xiao-Dan Ma

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Su, L. P., Wang, W. Y., Ma, X. D., & Hao, S. H. (2026). Dual Specificity Phosphatase 4 Enhances Immunotherapy Response by Inhibiting TGF-β1 Secretion in Hepatocellular Carcinoma. Cancers, 18(8), 1289. https://doi.org/10.3390/cancers18081289

Vancouver

Su LP, Wang WY, Ma XD, Hao SH. Dual Specificity Phosphatase 4 Enhances Immunotherapy Response by Inhibiting TGF-β1 Secretion in Hepatocellular Carcinoma. Cancers. 2026;18(8):1289. doi:10.3390/cancers18081289

BibTeX
@article{Su2026,
  author = {Su, Lian-Pan and Wang, Wei-Yi and Ma, Xiao-Dan and Hao, Shi-Hui},
  title = {Dual Specificity Phosphatase 4 Enhances Immunotherapy Response by Inhibiting TGF-β1 Secretion in Hepatocellular Carcinoma},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {1289},
  doi = {10.3390/cancers18081289}
}
Kostenlos starten →